ArticleStem cells translational medicine2019
Long-Term Results of Cultured Limbal Stem Cell Versus Limbal Tissue Transplantation in Stage III Limbal Deficiency.
Article in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01619189 (Thérapie Cellulaire au Cours Des Syndromes d'Insuffisance en Cellules Souches Limbiques), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Thérapie Cellulaire au Cours Des Syndromes d'Insuffisance en Cellules Souches Limbiques
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Outcomes of Limbal Stem Cell Transplant: A Meta-analysis.JAMA ophthalmology · 2020Pooled it
- Corneal regenerative contribution of endogenous and grafted limbal-corneal cells in a mouse model of simple limbal-corneal epithelial transplantation.Stem cells translational medicine · 2026Article
- Outcomes of allogeneic ocular surface stem cell transplantation.Frontiers in ophthalmology · 2026Review
- Oculoplastic Interventions in the Management of Ocular Surface Diseases: A Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Transdifferentiation of rat keratinocyte progenitors to corneal epithelial cells by limbal niche via the STAT3/PI3K/AKT signaling pathway.Stem cell research & therapy · 2025Article
- Progress in Transdifferentiation of Autologous Alternative Cell Sources into Corneal Epithelial Cells.Stem cell reviews and reports · 2025Review
- Tackling visual impairment: emerging avenues in ophthalmology.Frontiers in medicine · 2025Review
- The application of a 4D-printed chitosan-based stem cell carrier for the repair of corneal alkali burns.Stem cell research & therapy · 2024Article
- Ocular Surface Regeneration by Limbal Stem Cells Therapies: State of the Art, Challenges, and Perspectives.Stem cells translational medicine · 2023Article
- Cultivated autologous limbal epithelial cell (CALEC) transplantation: Development of manufacturing process and clinical evaluation of feasibility and safety.Science advances · 2023Article
- Concise Review: Bioengineering of Limbal Stem Cell Niche.Bioengineering (Basel, Switzerland) · 2023Review
- The immunology of corneal limbal stem cells: the up-to-date approach to stem cell transplantation.Central-European journal of immunology · 2023Review
- Review
- Induction of Corneal Epithelial Differentiation of Induced Pluripotent and Orbital Fat-Derived Stem Cells Seeded on Decellularized Human Corneas.Stem cell reviews and reports · 2022Article
- Cultivated Autologous Limbal Epithelial Cell Transplantation: New Frontier in the Treatment of Limbal Stem Cell Deficiency.American journal of ophthalmology · 2022Review
- Current and Emerging Therapies for Limbal Stem Cell Deficiency.Stem cells translational medicine · 2022Article
- Regenerative therapy for the Cornea.Progress in retinal and eye research · 2022Review
- Human limbal epithelial stem cell regulation, bioengineering and function.Progress in retinal and eye research · 2021Review
- Long-term survival of cultivated oral mucosal epithelial cells in human cornea: generating cell sheets using an animal product-free culture protocol.Stem cell research & therapy · 2021Article
- A Decellularized Human Limbal Scaffold for Limbal Stem Cell Niche Reconstruction.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to evaluate efficiency and safety of transplantation of limbal stem cells (LSC) cultured on human amniotic membrane with no feeders and to compare cultured LSC with limbal tissue transplantation. Thirty eyes with stage III LSC deficiency were treated with autologous (autoLSC) or allogeneic (alloLSC) cultured LSC transplantation (prospective phase II clinical trial; average follow-up time, 72 months) or autologous (autoLT) or allogeneic (alloLT) limbal tissue transplantation (retrospective control group; average follow-up time, 132 months) between 1993 and 2014. The 5-year graft survival defined by absence of recurrence of the clinical signs of limbal deficiency was 71% for autoLSC, 0% for alloLSC, 75% for autoLT, and 33% for alloLT. Visual acuity improved by 9.2 lines for autoLSC and 3.3 lines for autoLT. It decreased by 0.7 lines for alloLSC and 1.9 lines for alloLT. Adverse events were recorded in 1/7 autoLSC, 7/7 alloLSC, 6/8 autoLT, and 8/8 alloLT patients. Corneal epithelial defect was the only adverse event recorded after autoLSC, whereas severe sight-threatening adverse events were recorded in the remaining three groups. Compared with failed grafts, successful grafts featured greater decrease in fluorescein staining, greater superficial vascularization-free corneal area, lower variability of the corneal epithelial thickness, and higher corneal epithelial basal cell density. Autologous cultured LSC transplantation was associated with high long-term survival and dramatic improvement in vision and was very safe. Autologous limbal tissue transplantation resulted in similar efficiency but was less safe. Cadaver allogeneic grafts resulted in low long-term success rate and high prevalence of serious adverse events. Stem Cells Translational Medicine 2019;8:1230&1241.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.